Literature DB >> 1505929

Mucosal capillary thrombi in rectal biopsies.

A P Dhillon1, A Anthony, R Sim, A J Wakefield, E A Sankey, M Hudson, M C Allison, R E Pounder.   

Abstract

We studied the initial rectal biopsy from 46 patients in whom subsequent follow-up established the diagnosis of either self-limited colitis or inflammatory bowel disease. An additional 12 non-inflamed rectal biopsies were also studied. There was between 2 and 8 years of follow-up in each of these cases. Staining for fibrin (MSB, fibrinogen), platelets (factor XIIIA, Y2/51), and capillary basement membrane (reticulin, collagen 4) was performed to identify thrombotic material within capillaries. Mucosal capillary thrombi were best identified by staining for factor XIIIA; thrombi were observed in 8/13 cases of ulcerative colitis, 4/10 cases of Crohn's disease, 1/3 cases of unspecified inflammatory bowel disease and 5/20 cases of self-limited colitis. The presence of capillary thrombi was not related to the severity of inflammation, but none of the control biopsies showed capillary thrombi. Their presence seems of little diagnostic value in distinguishing inflammatory bowel disease from self-limited colitis. The pathogenetic significance of these mucosal capillary thrombi is uncertain.

Entities:  

Mesh:

Year:  1992        PMID: 1505929     DOI: 10.1111/j.1365-2559.1992.tb00360.x

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  34 in total

1.  A comprehensive analysis of 12 thrombophilic mutations and related parameters in patients with inflammatory bowel disease: data from Turkey.

Authors:  Serif Yilmaz; Kadim Bayan; Yekta Tüzün; Sabri Batun; Abdullah Altintaş
Journal:  J Thromb Thrombolysis       Date:  2006-12       Impact factor: 2.300

2.  Elevated plasma cryofibrinogen in patients with active inflammatory bowel disease is morbigenous.

Authors:  Koji Sawada; Ryouki Takahashi; Abbi R Saniabadi; Maiko Ohdo; Takashi Shimoyama
Journal:  World J Gastroenterol       Date:  2006-03-14       Impact factor: 5.742

3.  Platelet hyaluronidase-2 regulates the early stages of inflammatory disease in colitis.

Authors:  Aaron C Petrey; Dana R Obery; Sean P Kessler; Ash Zawerton; Bruno Flamion; Carol A de la Motte
Journal:  Blood       Date:  2019-07-01       Impact factor: 22.113

4.  Elevated plasma von Willebrand factor levels in patients with active ulcerative colitis reflect endothelial perturbation due to systemic inflammation.

Authors:  Petros Zezos; Georgia Papaioannou; Nikolaos Nikolaidis; Themistoclis Vasiliadis; Olga Giouleme; Nikolaos Evgenidis
Journal:  World J Gastroenterol       Date:  2005-12-28       Impact factor: 5.742

Review 5.  Multiple pathogenic roles of microvasculature in inflammatory bowel disease: a Jack of all trades.

Authors:  Livija Deban; Carmen Correale; Stefania Vetrano; Alberto Malesci; Silvio Danese
Journal:  Am J Pathol       Date:  2008-05-05       Impact factor: 4.307

Review 6.  Environmental factors in the relapse and recurrence of inflammatory bowel disease: a review of the literature.

Authors:  Thomas D Martin; Simon S M Chan; Andrew R Hart
Journal:  Dig Dis Sci       Date:  2014-11-19       Impact factor: 3.199

7.  Increased levels of homocysteine in patients with ulcerative colitis.

Authors:  Sabiye Akbulut; Emin Altiparmak; Firdevs Topal; Ersan Ozaslan; Metin Kucukazman; Ozlem Yonem
Journal:  World J Gastroenterol       Date:  2010-05-21       Impact factor: 5.742

Review 8.  Multipotent role of platelets in inflammatory bowel diseases: a clinical approach.

Authors:  Evangelos Voudoukis; Konstantinos Karmiris; Ioannis E Koutroubakis
Journal:  World J Gastroenterol       Date:  2014-03-28       Impact factor: 5.742

9.  Medical treatment of ulcerative colitis.

Authors:  Uma Mahadevan
Journal:  Clin Colon Rectal Surg       Date:  2004-02

Review 10.  Intestinal hypoxia and hypoxia-induced signalling as therapeutic targets for IBD.

Authors:  Sophie Van Welden; Andrew C Selfridge; Pieter Hindryckx
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-08-30       Impact factor: 46.802

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.